← Back to guidelines
Cardiology2 papers

Severe aortic valve stenosis

Last edited: 29 days ago

Overview

Severe aortic valve stenosis is characterized by significant narrowing of the aortic valve, leading to reduced cardiac output and symptoms such as angina, syncope, and heart failure. It predominantly affects elderly patients and requires careful management due to high surgical risk in many cases 1.

Diagnosis

  • Clinical Symptoms: Dyspnea, angina, syncope, exercise intolerance 1.
  • Echocardiography: Essential for assessing valve area, mean gradient, and valve morphology 1.
  • Grading: Based on valve area (typically <1 cm2), mean gradient (>40 mmHg), and velocity (>4 m/s) 1.
  • Management

  • Transcatheter Aortic Valve Replacement (TAVR): Recommended for high-risk surgical candidates 1.
  • Surgical Aortic Valve Replacement (SAVR): Preferred for lower-risk patients with suitable anatomy 1.
  • Medical Management: Focus on symptom relief and management of comorbidities (e.g., hypertension, heart failure) 1.
  • Impella Support: Used in high-risk percutaneous coronary interventions but requires careful monitoring to prevent complications like mitral chordae rupture 1.
  • Special Populations

  • Elderly Patients: High prevalence; TAVR is increasingly favored due to lower surgical risk 1.
  • Comorbidities: Presence of comorbidities influences treatment choice, favoring TAVR in high-risk surgical scenarios 1.
  • Key Recommendations

  • Consider TAVR for high-risk surgical candidates to improve survival and quality of life (Evidence: Moderate 1).
  • Echocardiographic monitoring is crucial during Impella support to prevent and manage complications such as mitral regurgitation (Evidence: Weak 1).
  • TAVR can serve as a rescue therapy for severe mitral regurgitation following complications like chordae rupture in high-risk patients (Evidence: Expert opinion 1).
  • References

    1 Pivato CA, Ferrante G, Briani M, Sanz Sanchez J, Reimers B, Pagnotta P. MitraClip Treatment for Severe Mitral Regurgitation Due to Chordae Rupture Following Impella CP Support in a Patient With Severe Aortic Stenosis. Cardiovascular revascularization medicine : including molecular interventions 2021. link

    Original source

    1. [1]
      MitraClip Treatment for Severe Mitral Regurgitation Due to Chordae Rupture Following Impella CP Support in a Patient With Severe Aortic Stenosis.Pivato CA, Ferrante G, Briani M, Sanz Sanchez J, Reimers B, Pagnotta P Cardiovascular revascularization medicine : including molecular interventions (2021)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG